Knowledge of the horizon: a meta-analysis of evaluating mortality incidence in multiple modalities therapy for metastatic renal cell carcinoma
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250990Keywords:
Renal cell carcinoma, Metastatic, TherapyAbstract
The treatment landscape for metastatic renal cell carcinoma (mRCC) has improved with advances in targeted therapy, immunotherapy, and surgical interventions, each showing survival benefits. Although these approaches, used singly or in combination, improve outcomes, the optimal strategy remains to be determined. Yet, limited comparisons across strategies create a need to identify the most effective treatments for mRCC patients. To address this, we conducted a meta-analysis to evaluate combined surgical, targeted, and systemic therapies for mRCC, focusing on survival and mortality risk. Our aim was to offer insights that could guide future treatment approaches and improve patient outcomes. This meta-analysis was performed based on the PRISMA guidelines. Statistical analysis for meta-analyses using dichotomous types. To analyse clinical studies reporting the use of combination therapy (surgery and systemic intervention) for evaluating mortality incidence in mRCC, a systematic search was performed using three electronic databases (PubMed, Science Direct, and Google Scholar). Ten years of studies, English full paper text, and original research retrospective study design were included. Statistical analyses using Review Manager Application 5.4.1 version. From 1019 studies, there are eleven studies were eligible in this meta-analysis and have a low risk of bias. Ten studies comprising 2644 patients were included in this study for qualitative and quantitative analysis. Ten studies report the use of Combination Therapy (surgery and systemic intervention) for evaluating mortality incidence in mRCC. Quantitative synthesis showed Combination intervention was associated with death incidence in metastatic events in renal cell carcinoma with odds ratio (OR) 1.46 (95% CI; 1.37-1,54; I2=98%, p value=<0,0001). Furthermore, this research is still found to be qualitatively controversial. Our review indicates that combination therapies for mRCC improve survival outcomes but entail complex mortality risks. Further research is needed to refine therapy combinations and patient selection, underscoring a personalized approach to balance benefits with risks.
Metrics
References
Baston C, Parosanu AI, Stanciu IM, Nitipir C. Metastatic kidney cancer: Does the location of the metastases matter? Moving towards personalized therapy for metastatic renal cell carcinoma. Biomed. 2024;12(5):1111. DOI: https://doi.org/10.3390/biomedicines12051111
Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, et al. Combination therapy in renal cell carcinoma: the best choice for every patient. Current Oncol Rep. 2021;23:1-2. DOI: https://doi.org/10.1007/s11912-021-01140-9
Logan JE, Rampersaud EN, Sonn GA. Systemic therapy for metastatic renal cell carcinoma: A review and update. Reviews in Urol. 2012;14(3):65–78.
Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urol. 2014;66(4):704-10. DOI: https://doi.org/10.1016/j.eururo.2014.05.034
Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clinical Genitourinary Cancer. 2015;13(3):159-66. DOI: https://doi.org/10.1016/j.clgc.2014.12.017
Gershman B, Moreira DM, Boorjian SA, Lohse CM, Cheville JC, Costello BA, et al. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. European Urol. 2016;69(1):84-91. DOI: https://doi.org/10.1016/j.eururo.2015.05.022
Groot S, Redekop WK, Sleijfer S, Oosterwijk E, Bex A, Kiemeney LA, et al. Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: results from a population-based registry. Urol. 2016;95:121-7. DOI: https://doi.org/10.1016/j.urology.2016.04.042
Blute ML, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, et al. tumor burden does not predict overall survival following cytoreductive nephrectomy for renal cell carcinoma: a novel 3-dimensional volumetric analysis. Urology. 2017;100:139-44. DOI: https://doi.org/10.1016/j.urology.2016.09.016
Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, et al. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. European J of Cancer. 2017;80:55-62. DOI: https://doi.org/10.1016/j.ejca.2017.03.011
Lyon TD, Gershman B, Shah PH, Thompson RH, Boorjian SA, Lohse CM, et al. Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. In Urol Oncol Sem Or Investig. 2018;36(11):499-501. DOI: https://doi.org/10.1016/j.urolonc.2018.08.008
Bhindi B, Graham J, Wells JC, Bakouny Z, Donskov F. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. European Urol. 2020;4:38 DOI: https://doi.org/10.1016/j.eururo.2020.04.038
Singla N, Hutchinson RC, Ghandour RA, Freifeld Y, Fang D. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urologic Oncol. 2020;2:29 DOI: https://doi.org/10.1016/j.urolonc.2020.02.029
Escudier B, de Zélicourt M, Bourouina R, Nevoret C, Thiery-Vuillemin A. Management and health resource use of patients with metastatic renal cell carcinoma treated with systemic therapy over 2014–2017 in France: A national real-world study. Clin Genitourin Cancer. 2022;20(6):533-42. DOI: https://doi.org/10.1016/j.clgc.2022.07.010
Downloads
Published
How to Cite
Issue
Section
